New developments in sustained-release antihypertensive therapy: formulation and pharmacokinetic considerations.
In order to achieve a consistently absorbed form of nifedipine over 24 hours, a novel formulation approach, INDAS, was used to develop a once-daily, sustained-release (SR) form of nifedipine that could provide effective control of blood pressure at a low total daily dose. The pharmacokinetic characteristics of this new formulation of nifedipine-SR were compared with those of divided doses of conventional nifedipine. The SR formulation was shown to achieve a lower peak plasma nifedipine level but with a prolonged plasma profile characterized by an extended time to peak plasma levels (Tmax), a higher trough plasma level, a longer apparent half-life, and a markedly lower peak-to-trough fluctuation in plasma nifedipine concentrations. In a separate study, the gastrointestinal transit parameters and physical characteristics of the SR tablet were evaluated. This study established that the large intestine is the major site of residence and absorption for this dosage form. The physical erosion and disintegration characteristics of the SR formulation are such that a well-maintained absorption of nifedipine is consistently achieved over the 24 hour dosing interval.
Devane
J G
JG
Elan Pharmaceutical Research Corporation, Gainesville, Georgia 30504.
Mulligan
S
S
Kavanagh
M
M
Davis
S S
SS
Sparrow
R A
RA
Wilding
I R
IR
D000328:Adult; D000704:Analysis of Variance; D003692:Delayed-Action Preparations; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D012016:Reference Values
D003692:Delayed-Action Preparations; D009543:Nifedipine